Full Year 2023 Investor Presentation

5 Investor presentation Full year 2023 Sales growth of 36% driven by both operating units Reported geographic sales split for the full year 2023 Novo NordiskⓇ Reported therapy area sales and growth for the full year 2023 DKK billion Insulin Obesity care GLP-1 Rare disease Other diabetes DKK North America Operations International Operations ☐ Growth at CER billion Growth at CER 36% 52% -6% 154% -15% 150 54% 240 120 200 16% 16% International Operations 00 90 160 60 60 30 17% 120 53% 80 54% 15% IO 0% NAO -23% ΙΟ 47% NAO 212% 11% 52% 40 ΙΟ -24% NAO -1% 0 0 NAO ΙΟ EMEA China ROW Total GLP-1 Insulin Obesity care Rare disease IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations; CER: Constant exchange rates Note: Unless otherwise specified, sales growth rates are at CER 1'Other diabetes' is included in Total

View entire presentation